Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

CANCER:

Ampulla of Vater Carcinoma

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

KRAS G12C	Ampulla of Vater Carcinoma	KRAS G12C	Ampulla of Vater Carcinoma	sotorasib Sensitive: A2 - Guideline sotorasib Sensitive : A2	sotorasib Sensitive: A2 - Guideline sotorasib Sensitive : A2
BRAF V600E	Ampulla of Vater Carcinoma	BRAF V600E	Ampulla of Vater Carcinoma	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2
No biomarker	Ampulla of Vater Carcinoma	No biomarker	Ampulla of Vater Carcinoma	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2
No biomarker	Ampulla of Vater Carcinoma	No biomarker	Ampulla of Vater Carcinoma	5-fluorouracil + leucovorin calcium Sensitive: A2 - Guideline 5-fluorouracil + leucovorin calcium Sensitive : A2	5-fluorouracil + leucovorin calcium Sensitive: A2 - Guideline 5-fluorouracil + leucovorin calcium Sensitive : A2
RET fusion	Ampulla of Vater Carcinoma	RET fusion	Ampulla of Vater Carcinoma	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2
NTRK3 fusion	Ampulla of Vater Carcinoma	NTRK3 fusion	Ampulla of Vater Carcinoma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK2 fusion	Ampulla of Vater Carcinoma	NTRK2 fusion	Ampulla of Vater Carcinoma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK1 fusion	Ampulla of Vater Carcinoma	NTRK1 fusion	Ampulla of Vater Carcinoma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK1 fusion	Ampulla of Vater Carcinoma	NTRK1 fusion	Ampulla of Vater Carcinoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK2 fusion	Ampulla of Vater Carcinoma	NTRK2 fusion	Ampulla of Vater Carcinoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK3 fusion	Ampulla of Vater Carcinoma	NTRK3 fusion	Ampulla of Vater Carcinoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
No biomarker	Ampulla of Vater Carcinoma	No biomarker	Ampulla of Vater Carcinoma	durvalumab Sensitive: A2 - Guideline durvalumab Sensitive : A2	durvalumab Sensitive: A2 - Guideline durvalumab Sensitive : A2